Bial - Portela C
CompanyPortugal
Bial - Portela C develops one asset, in phase 1 (resveratrol in Parkinson's disease). Mostly small molecule acting on Oxidative stress and ROS signalling, Mitochondrial biogenesis (PGC-1α) and sirtuin signalling; based in Portugal.
- Assets
- 1
- Furthest
- Phase 1
- Trials
- 15
- Signals
- 0
Pipeline
1Polyphenolic compound that activates SIRT1 and AMPK, promoting antioxidant defenses and mitochondrial function.
Phase 1Small moleculeOxidative stress and ROS signallingMitochondrial biogenesis (PGC-1α)Parkinson's disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms7
- Trials15
- Similar companies6
Updated 7 Oct 2026 · 19 sources